Bharat Biotech’s iNCOVACC, world’s first Intra Nasal vaccine, gets emergency use approval in India

Heterologous booster dose studies were conducted for safety and immunogenicity in ~875 subjects at 9 trial sites across India

Hyderabad: Bharat Biotech International Limited (BBIL) has announced that its recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein, iNCOVACC (BBV154) has received approval under Restricted Use in Emergency Situation
for ages 18 and above. This is the world’s first intra nasal Covid-19 vaccine.
This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results. iNCOVACC has been specifically formulated to allow intranasal delivery through nasal drops. The nasal delivery system has been designed and developed to be cost effective in low- and middle-income countries.
iNCOVACC was developed in partnership with Washington University St. Louis, which had
designed and developed the recombinant adenoviral vectored constructs and evaluated
them in preclinical studies for efficacy. Product development related to preclinical safety
evaluation, large scale manufacturing scale up, formulation and delivery device
development, including human clinical trials were conducted by Bharat Biotech. Product
development and clinical trials were funded in part by the Government of India through the
Department of Biotechnology’s COVID Suraksha program.
Clinical trials were conducted to evaluate iNCOVACC as a primary dose schedule, as
heterologous booster dose for subjects who have previously received 2 doses of the two
commonly administered covid vaccines in India.
Immunogenicity was evaluated through serum neutralizing antibodies by PRNT assays and
serum IgG’s through ELISA’s. To evaluate vaccines taken through the intranasal route, IgA’s
were evaluated by ELISA in serum and saliva. Evaluation was also carried out for ability
iNCOVACC to elicit long term memory T and B cell responses against the ancestral and
omicron variants.
Dr. Krishna Ella, Chairman & Managing Director, Bharat Biotech, said, “We are proud to
announce the approval of iNCOVACC, a global game changer in Intra Nasal vaccines
technology and delivery systems. Despite the lack of demand for COVID-19 vaccines, we
continued product development in intra nasal vaccines to ensure that we are well prepared
with platform technologies for future infectious diseases. We thank the Ministry of Health,
the CDSCO, Dept of Biotechnology Govt of India, and Washington University St. Louis for
their support and guidance. iNCOVACC has been designed for efficient distribution and
easy administration.”
iNCOVACC was evaluated to determine its impact on safety. The reactogenic events and
adverse events that were documented during the trial were highly comparable to published
data from other covid-19 vaccines. Product development data will be submitted to peer
reviewed journals and will be made available in the public domain.
iNCOVACC has the double benefit of enabling faster development of variant specific
vaccines and easy nasal delivery that enables mass immunization to protect from emerging
variants of concern. It promises to become an important tool in mass vaccinations during
pandemics and endemics. With the receipt of approval today, the product will be launched
and available for use in due course of time.
iNCOVACC is stable at 2-8°C for easy storage and distribution. Bharat Biotech has
established large manufacturing capabilities at multiple sites across India, including Gujarat,
Karnataka, Maharashtra and Telangana with operations pan India